A novel eye drop platform and its use to treat Namd
- Global neovascular AMD market, estimated at $6.9 billion in 2018, is projected to reach $10.4 billion by 2024, registering a CAGR of 7.1% during the forecast period.
- Eye drop provides alternative self-care treatment for AMD patients compared to intravitreal(IVT) injection of VEGF antibodies by ophthalmologists.
- Proprietary combination of FDA approved excipients
- Increase drug solubility
- Show excellent ocular penetration
- No ocular irritation
Booth No. L1010